Quarterly report · Q2
4483.TEDINET S100S9E5
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.7bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥7.0bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.1bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.3bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥621m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥678m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥623m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥677m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥100.0bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥98.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥112.1bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥31.3bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥34.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥68.7bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥61.6bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥68.6bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥61.6bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥21.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥41.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥341m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥48.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥9.83 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥25.29 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.76 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥40.53 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥9.46 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥23.86 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.14 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 68.6% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥13m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥13m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥338m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥187m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥292m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥292m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥50m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥133m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥38m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥13m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥566m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥7.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥13.7bn |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥7.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥89m |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥13m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥189m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥99m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥933m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥890m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥84m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥192m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥144m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥24m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥903m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥924m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥485m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥6.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥6.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥126m |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥67m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 887
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 7062000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -13000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration | 7048000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember | 1197000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember | 566000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember | 45000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 1810000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -187000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration | 1623000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration | 1434000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration | 1623000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration | 491000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentQuarterDuration | 522000000 | JPY |
| Other income IFRS | Prior1QuarterDuration | 183000000 | JPY |
| Other income IFRS | CurrentQuarterDuration | 20000000 | JPY |
| Other expenses IFRS | Prior1QuarterDuration | 0 | JPY |
| Other expenses IFRS | CurrentQuarterDuration | 65000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration | 1126000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration | 1055000000 | JPY |
| Finance income IFRS | Prior1QuarterDuration | 13000000 | JPY |
| Finance income IFRS | CurrentQuarterDuration | 9000000 | JPY |
| Finance costs IFRS | Prior1QuarterDuration | 26000000 | JPY |
| Finance costs IFRS | CurrentQuarterDuration | 2000000 | JPY |
| Profit loss before tax IFRS | Prior1QuarterDuration | 1113000000 | JPY |
| Profit loss before tax IFRS | CurrentQuarterDuration | 1062000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第11期第２四半期（自 2023年７月１日 至 2023年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Company name in english cover page | FilingDateInstant | JMDC Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 兼 ＣＥＯ 野口 亮 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)上席執行役員 兼 ＣＦＯ 望月 智洋 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)上席執行役員 兼 ＣＦＯ 望月 智洋 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35308 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 44830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Filer name in english | FilingDateInstant | JMDC Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |